The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991

J Surg Oncol Suppl. 1993:3:78-82. doi: 10.1002/jso.2930530522.

Abstract

Experience with liver transplantation over a period of 11 years at the University of Pittsburgh is presented. The application of liver transplantation to cases of hepatocellular carcinoma has changed considerably over this 11-year period with the sequential introduction of adjuvant and, more recently, neoadjuvant chemotherapy. Results with the combination of chemotherapy plus surgery appear to be better than results with either agent alone. Moreover, the early results with neoadjuvant therapy appear to be better than those achieved with adjuvant therapy. As a result of this experience, conceptual changes in the approach to the problem of hepatic cancer and the role of both chemotherapy and liver transplantation in its management have changed at the University of Pittsburgh. These changes are identified and discussed.

MeSH terms

  • Adenoma, Bile Duct / drug therapy
  • Adenoma, Bile Duct / pathology
  • Adenoma, Bile Duct / surgery
  • Carcinoma / drug therapy
  • Carcinoma / pathology
  • Carcinoma / surgery
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / surgery*
  • Chemotherapy, Adjuvant
  • Hemangioendothelioma / drug therapy
  • Hemangioendothelioma / pathology
  • Hemangioendothelioma / surgery
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology
  • Liver Neoplasms / surgery*
  • Liver Transplantation / methods
  • Liver Transplantation / statistics & numerical data*
  • Pennsylvania / epidemiology
  • Survival Rate